DelveInsight’s Generalized Pustular Psoriasis (GPP) – Market Insights, Epidemiology and Market Forecast-2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Generalized Pustular Psoriasis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Generalized Pustular Psoriasis from 2017 to 2028 segmented by the seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Some of the key facts of the Generalized Pustular Psoriasis Market Report:
- As per a study by Mirza et al. (2021), The annual prevalence of GPP in a French population has been estimated at 1.76 per million. The prevalence in Japan has been estimated at 7.46 per million.
- According to Gordan et al. (2022), the prevalence of GPP is between 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect as many as 12% of those who have plaque psoriasis, and moreover, 70% of patients who have GPP also have plaque psoriasis.
- As per a study by Lebwohl et al. (2022), GPP is a rare disease, with a reported prevalence of between 0.01 and 0.02/10,000 in France to 5/10,000 in Germany.
- In a study by Twelves et al. (2019), about half of GPP cases were concomitant with psoriasis Vulgaris. GPP is more frequent in women than in men, with male-to-female ratios of 0.5–0.9. GPP seems to occur in all ages, and mean age at onset has been found to be between 40 and 50 years
- As per Noe et al. (2021), GPP is quite rare in the U.S. For example, five study sites (25%) did not have 5 GPP cases during the 10-year study period. It is more common in women (70%) and is highly burdensome.
Key benefits of the Generalized Pustular Psoriasis Market report:
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Generalized Pustular Psoriasis market
- Organize sales and marketing efforts by identifying the best opportunities for the Generalized Pustular Psoriasis market
- To understand the future market competition in the GPP market.
Got queries? Click here to know more about the Generalized Pustular Psoriasis Market Landscape
Generalized Pustular Psoriasis Overview
Generalized Pustular Psoriasis (GPP) is a subtype of pustular psoriasis characterized by sudden, repeated episodes of high-grade fever, generalized erythematous pustular rashes, painful and occasionally disfiguring cutaneous manifestations with sepsis-like.
Psoriasis is an immune-mediated disease that is clinically classified into two groups: pustular and non-pustular lesions. Non-pustular psoriasis is further subdivided into Psoriasis vulgaris (early and late onset), Guttate psoriasis, Erythrodermic psoriasis, Palmoplantar psoriasis, Psoriatic arthritis (PsA), and Inverse psoriasis. The Pustular variant of the psoriasis is further subdivided into generalized and localized forms.
GPP is a rare, severe, and potentially life-threatening variant of psoriasis that has been associated with abnormalities in the cytokine (messenger protein) interleukin-36 receptor-antagonist signaling. This is due to recessive IL36RN gene mutations, systemic symptoms and systemic upset.
Generalized Pustular Psoriasis Epidemiological Insights:
- As per a study by Mirza et al. (2021), The annual prevalence of GPP in a French population has been estimated at 1.76 per million. The prevalence in Japan has been estimated at 7.46 per million.
- According to Gordan et al. (2022), the prevalence of GPP is between 0.004% to 0.046% and this condition has a mortality range of 2% to 16%. Gordon also said that it may affect as many as 12% of those who have plaque psoriasis, and moreover, 70% of patients who have GPP also have plaque psoriasis.
Generalized Pustular Psoriasis Epidemiological Segmentation
- Generalized pustular psoriasis total prevalent population
- Generalized pustular psoriasis stage-specific incident
- Generalized pustular psoriasis severity-specific diagnosed Prevalent cases
- Generalized pustular psoriasis age-specific diagnosed prevalent population
Generalized Pustular Psoriasis Market Outlook
The Generalized Pustular Psoriasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of GPP in the seven major markets is expected to grow at a CAGR of 10.16% for the study period (2017-2028). The current therapeutic landscape of GPP in the United States is driven by supportive therapies (topical therapies, systemic therapies, biologics and phototherapy). In EU-5 countries, for GPP, the market is same as that of the US, with prescriptions for supportive therapies, due to lack of approved treatment regimens, and together accounted for nearly USD 20.21 million in 2017. In contrast to the US and EU-5 countries, the current therapeutic landscape of GPP in Japan is driven by a number of approved therapies, along with supportive treatment regimens.
Learn more by requesting for sample @Generalized Pustular Psoriasis Market Landscape
Generalized Pustular Psoriasis Key Companies
- AbbVie
- Kyowa Pharma
- Novartis
- Eilly Lilly
- Mitsubishi Tanabe Pharma
- Boehringer Ingelheim
- Janssen Pharmaceuticals
- And others.
Generalized Pustular Psoriasis Therapies
- Tremfya
- SKYRIZI
- HUMIRA
- Lumicef
- Cosnetyx
- Remicade
- Ixekizumab
- And others.
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Generalized Pustular Psoriasis
- Disease Background and Overview
- Epidemiology and patient population
- Generalized Pustular Psoriasis Emerging Therapies
- Generalized Pustular Psoriasis Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Generalized Pustular Psoriasis Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Click here to read more about Generalized Pustular Psoriasis Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/